journal
https://read.qxmd.com/read/38661612/functional-single-cell-analyses-of-mesenchymal-stromal-cell-proliferation-and-differentiation-using-aldh-activity-and-mitochondrial-ros-content
#1
JOURNAL ARTICLE
Alice Refeyton, Véronique Labat, Margaux Mombled, Marija Vlaski-Lafarge, Zoran Ivanovic
BASKGROUND: Previous research has unveiled a stem cell-like transcriptome enrichment in the aldehyde dehydrogenase-expressing (ALDHhigh ) mesenchymal stromal cell (MStroC) fraction. However, considering the heterogeneity of MStroCs, with only a fraction of them presenting bona fide stem cells (MSCs), the actual potency of ALDH as an MSC-specific selection marker remains an issue. METHODS: To address this, the proliferative and differentiation potential of individual ALDHhigh and ALDHlow MStroCs incubated at low oxygen concentrations, estimated to mimic stem cell niches (0...
April 10, 2024: Cytotherapy
https://read.qxmd.com/read/38661611/optimizing-lentiviral-vector-formulation-conditions-for-efficient-ex-vivo-transduction-of-primary-human-t-cells-in-chimeric-antigen-receptor-t-cell-manufacturing
#2
JOURNAL ARTICLE
Annu Luostarinen, Anssi Kailaanmäki, Vesa Turkki, Marjut Köylijärvi, Piia Käyhty, Hanna Leinonen, Vita Albers-Skirdenko, Eevi Lipponen, Seppo Ylä-Herttuala, Tanja Kaartinen, Hanna P Lesch, Tuija Kekarainen
BACKGROUND AIMS: Chimeric antigen receptor (CAR) T-cell products are commonly generated using lentiviral vector (LV) transduction. Optimal final formulation buffer (FFB) supporting LV stability during cryostorage is crucial for cost-effective manufacturing. METHODS: To identify the ideal LV FFB composition for ex vivo CAR-T production, primary human T cells were transduced with vesicular stomatitis virus G-protein (VSV-G) -pseudotyped LVs (encoding a reporter gene or an anti-CD19-CAR)...
April 7, 2024: Cytotherapy
https://read.qxmd.com/read/38639670/adipose-derived-stromal-vascular-fraction-cells-to-treat-long-term-pulmonary-sequelae-of-coronavirus-disease-2019-12-month-follow-up
#3
JOURNAL ARTICLE
Michael Carstens, Jessy Trujillo, Yanury Dolmus, Carlos Rivera, Santos Calderwood, Judith Lejarza, Carlos López, Kenneth Bertram
BACKGROUND AIMS: Long coronavirus disease (COVID) is estimated to occur in up to 20% of patients with coronavirus disease 2019 (COVID-19) infections, with many having persistent pulmonary symptoms. Mesenchymal stromal cells (MSCs) have been shown to have powerful immunomodulatory and anti-fibrotic properties. Autologous adipose-derived (AD) stromal vascular fraction (SVF) contains MSC and other healing cell components and can be obtained by small-volume lipoaspiration and administered on the same day...
April 4, 2024: Cytotherapy
https://read.qxmd.com/read/38613540/consensus-guidelines-for-the-monitoring-and-management-of-metachromatic-leukodystrophy-in-the-united-states
#4
JOURNAL ARTICLE
Laura A Adang, Joshua L Bonkowsky, Jaap Jan Boelens, Eric Mallack, Rebecca Ahrens-Nicklas, John A Bernat, Annette Bley, Barbara Burton, Alejandra Darling, Florian Eichler, Erik Eklund, Lisa Emrick, Maria Escolar, Ali Fatemi, Jamie L Fraser, Amy Gaviglio, Stephanie Keller, Marc C Patterson, Paul Orchard, Jennifer Orthmann-Murphy, Jonathan D Santoro, Ludger Schöls, Caroline Sevin, Isha N Srivastava, Deepa Rajan, Jennifer P Rubin, Keith Van Haren, Melissa Wasserstein, Ayelet Zerem, Francesca Fumagalli, Lucia Laugwitz, Adeline Vanderver
Metachromatic leukodystrophy (MLD) is a fatal, progressive neurodegenerative disorder caused by biallelic pathogenic mutations in the ARSA (Arylsulfatase A) gene. With the advent of presymptomatic diagnosis and the availability of therapies with a narrow window for intervention, it is critical to define a standardized approach to diagnosis, presymptomatic monitoring, and clinical care. To meet the needs of the MLD community, a panel of MLD experts was established to develop disease-specific guidelines based on healthcare resources in the United States...
April 1, 2024: Cytotherapy
https://read.qxmd.com/read/38678462/ex-vivo-expanded-cd34-cell-transplantation-alleviates-fibrotic-liver-injury-via-innate-immune-modulation-in-metabolic-dysfunction-associated-steatohepatitis-mice
#5
JOURNAL ARTICLE
Atsutaka Masuda, Toru Nakamura, Hideki Iwamoto, Hiroyuki Suzuki, Takahiko Sakaue, Toshimitsu Tanaka, Yasuko Imamura, Nobuyuki Mori, Hironori Koga, Takumi Kawaguchi
BACKGROUND: In drug-induced liver injury, vascular endothelial progenitor cells, specifically the CD34+ cell fractions, have been found to decrease liver fibrosis and promote regeneration. However, it is unclear whether CD34+ cell transplantation has anti-fibrogenic effects on MASH, which has previously been treated effectively with anti-angiogenic therapy. We investigated the efficacy of ex vivo-expanded CD34+ cells in treating MASH livers. MATERIALS AND METHODS: Diet-induced MASH mice were fed a choline-deficient, L-amino acid-defined, high-fat diet for 12 or 20 weeks, and were designated as a mild and a severe fibrosis model, respectively...
March 30, 2024: Cytotherapy
https://read.qxmd.com/read/38639671/allogeneic-transplantation-of-bone-marrow-versus-peripheral-blood-stem-cells-from-hla-identical-sibling-donors-for-hematological-malignancies-in-6064-adults-from-2003-to-2020-different-impacts-on-survival-according-to-time-period
#6
JOURNAL ARTICLE
Takaaki Konuma, Kotaro Miyao, Hideki Nakasone, Fumihiko Ouchi, Takahiro Fukuda, Masatsugu Tanaka, Yukiyasu Ozawa, Shuichi Ota, Toshiro Kawakita, Naoyuki Uchida, Masashi Sawa, Yuta Katayama, Nobuhiro Hiramoto, Tetsuya Eto, Tatsuo Ichinohe, Yoshiko Atsuta, Junya Kanda
BACKGROUND: Mobilized peripheral blood stem cells (PBSC) have been widely used instead of bone marrow (BM) as the graft source for allogeneic hematopoietic cell transplantation (HCT). Although early studies demonstrated no significant differences in survival between PBSC transplantation (PBSCT) and BM transplantation (BMT) from human leukocyte antigen (HLA)-identical sibling donors to adults with hematological malignancies, recent results have been unclear. OBJECTIVE: The objective of this retrospective study was to compare overall survival (OS), relapse, non-relapse mortality (NRM), hematopoietic recovery and graft-versus-host disease (GVHD) between PBSCT and BMT according to the time period of HCT (2003-2008, 2009-2014, or 2015-2020)...
March 30, 2024: Cytotherapy
https://read.qxmd.com/read/38639669/synthetic-biology-approaches-for-enhancing-safety-and-specificity-of-car-t-cell-therapies-for-solid-cancers
#7
JOURNAL ARTICLE
Grace C Russell, Yassin Hamzaoui, Daniel Rho, Gaurav Sutrave, Joseph S Choi, Dara S Missan, Gabrielle A Reckard, Michael P Gustafson, Gloria B Kim
CAR-T cell therapies have been successful in treating numerous hematologic malignancies as the T cell can be engineered to target a specific antigen associated with the disease. However, translating CAR-T cell therapies for solid cancers is proving more challenging due to the lack of truly tumor-associated antigens and the high risk of off-target toxicities. To combat this, numerous synthetic biology mechanisms are being incorporated to create safer and more specific CAR-T cells that can be spatiotemporally controlled with increased precision...
March 30, 2024: Cytotherapy
https://read.qxmd.com/read/38625069/investigation-of-biomarkers-to-predict-outcomes-in-allogeneic-hematopoietic-stem-cell-transplantation
#8
JOURNAL ARTICLE
Takayoshi Tachibana, Takuya Miyazaki, Ayako Matsumura, Maki Hagihara, Masatsugu Tanaka, Satoshi Koyama, Eriko Ogusa, Jun Aoki, Yuki Nakajima, Hiroyuki Takahashi, Taisei Suzuki, Yoshimi Ishii, Haruka Teshigawara, Kenji Matsumoto, Mayumi Hatayama, Akihiko Izumi, Katsuya Ikuta, Koji Yamamoto, Heiwa Kanamori, Shin Fujisawa, Hideaki Nakajima
BACKGROUND: Various biomarkers have been developed and evaluated to predict the prognosis and complications of allogeneic hematopoietic cell transplantation (HCT). Most previous studies conducted on different biomarkers evaluated single effects such as those associated with inflammation, immunology, iron metabolism, and nutrition, and only a few studies have comprehensively analyzed markers. OBJECTIVE: The study aimed to survey comprehensive multiple markers prior to HCT and extract those that significantly predict the outcomes...
March 30, 2024: Cytotherapy
https://read.qxmd.com/read/38625068/neutrophil-generation-from-hematopoietic-progenitor-cells-and-induced-pluripotent-stem-cells-ipscs-potential-applications
#9
REVIEW
Abdollah Jafarzadeh, Marzieh Motaghi, Sanand Kumar Patra, Zahra Jafarzadeh, Maryam Nemati, Bhaskar Saha
Neutrophils are the most frequent immune cell type in peripheral blood, performing an essential role against pathogens. People with neutrophil deficiencies are susceptible to deadly infections, highlighting the importance of generating these cells in host immunity. Neutrophils can be generated from hematopoietic progenitor cells (HPCs) and embryonic stem cells (ESCs) using a cocktail of cytokines. In addition, induced pluripotent stem cells (iPSCs) can be differentiated into various functional cell types, including neutrophils...
March 30, 2024: Cytotherapy
https://read.qxmd.com/read/38583169/substrate-elasticity-does-not-impact-dna-methylation-changes-during-differentiation-of-pluripotent-stem-cells
#10
JOURNAL ARTICLE
Mohamed H Elsafi Mabrouk, Kira Zeevaert, Ann-Christine Henneke, Catharina Maaßen, Wolfgang Wagner
BACKGROUND AIMS: Substrate elasticity may direct cell-fate decisions of stem cells. However, it is largely unclear how matrix stiffness affects the differentiation of induced pluripotent stem cells (iPSCs) and whether this is also reflected by epigenetic modifications. METHODS: We cultured iPSCs on tissue culture plastic (TCP) and polydimethylsiloxane (PDMS) with different Young's modulus (0.2 kPa, 16 kPa or 64 kPa) to investigate the sequel on growth and differentiation toward endoderm, mesoderm and ectoderm...
March 30, 2024: Cytotherapy
https://read.qxmd.com/read/38639672/challenges-and-opportunities-for-access-to-advanced-therapy-medicinal-products-in-brazil
#11
JOURNAL ARTICLE
Camile Giaretta Sachetti, Augusto Barbosa, Antonio Carlos Campos de Carvalho, Denizar Vianna Araujo, Everton Nunes da Silva
BACKGROUND AIMS: The marketing authorization of Advanced Therapy Medicinal Products (ATMPs) in Brazil is recent. The features of these therapies impose specialized regulatory action and are consequently challenging for developers. The goal of this study was to identify the industry's experience in clinical development, marketing authorization and access to ATMPs through the Unified Health System (SUS, acronym in Portuguese), from a regulatory perspective. METHODS: A survey containing structured questions was conducted among research participants who work at companies that commercialize ATMPs...
March 29, 2024: Cytotherapy
https://read.qxmd.com/read/38625072/complex-association-of-body-mass-index-and-outcomes-in-patients-with-relapsed-and-refractory-multiple-myeloma-treated-with-car-t-cell-immunotherapy
#12
JOURNAL ARTICLE
Hai Cheng, Yingjun Sun, Xiaoxue Zhang, Zihan Chen, Lingyan Shao, Jiaying Liu, Dandan Wang, Yegan Chen, Xue Wang, Wei Chen, Wei Sang, Kunming Qi, Zhenyu Li, Cai Sun, Ming Shi, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Junnian Zheng, Kailin Xu, Jiang Cao
BACKGROUND AIMS: Chimeric antigen receptor-T (CAR-T) cells have exhibited remarkable efficacy in treating refractory or relapsed multiple myeloma (R/R MM). Although obesity has a favorable value in enhancing the response to immunotherapy, less is known about its predictive value regarding the efficacy and prognosis of CAR-T cell immunotherapy. METHODS: We conducted a retrospective study of 111 patients with R/R MM who underwent CAR-T cell treatment. Using the body mass index (BMI) classification, the patients were divided into a normal-weight group (73/111) and an overweight group (38/111)...
March 29, 2024: Cytotherapy
https://read.qxmd.com/read/38625070/adipose-derived-stem-cell-modulate-tolerogenic-dendritic-cell-induced-t-cell-regulation-is-correlated-with-activation-of-notch-nf%C3%AE%C2%BAb-signaling
#13
JOURNAL ARTICLE
Yu-Chi Wang, Rong-Fu Chen, Keng-Fan Liu, Wei-Yu Chen, Chia-Chun Lee, Yur-Ren Kuo
BACKGROUND: Adipose-derived stem cells (ASCs) are recognized for their potential immunomodulatory properties. In the immune system, tolerogenic dendritic cells (DCs), characterized by an immature phenotype, play a crucial role in inducing regulatory T cells (Tregs) and promoting immune tolerance. Notch1 signaling has been identified as a key regulator in the development and function of DCs. However, the precise involvement of Notch1 pathway in ASC-mediated modulation of tolerogenic DCs and its impact on immune modulation remain to be fully elucidated...
March 29, 2024: Cytotherapy
https://read.qxmd.com/read/38597860/phenotypic-and-functional-characterization-of-posoleucel-a-multivirus-specific-t-cell-therapy-for-the-treatment-and-prevention-of-viral-infections-in-immunocompromised-patients
#14
JOURNAL ARTICLE
Spyridoula Vasileiou, Manik Kuvalekar, Yovana Velazquez, Ayumi Watanabe, Ann M Leen, Sarah A Gilmore
BACKGROUND: Deficits in T cell immunity translate into increased risk of severe viral infection in recipients of solid organ and hematopoietic cell transplants. Thus, therapeutic strategies that employ the adoptive transfer of virus-specific T cells are being clinically investigated to treat and prevent viral diseases in these highly immunocompromised patients. Posoleucel is an off-the-shelf multivirus-specific T cell investigational product for the treatment and prevention of infections due to adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6 or JC virus...
March 19, 2024: Cytotherapy
https://read.qxmd.com/read/38583170/accelerating-the-development-of-genetically-engineered-cellular-therapies-a-framework-for-extrapolating-data-across-related-products
#15
JOURNAL ARTICLE
Mark D Stewart, Michael Kalos, Vicki Coutinho, Marc Better, Jonathan Jazayeri, Jennifer Yohrling, Julie Jadlowsky, Miriam Fuchs, Shalini Gidwani, Carsten Goessl, Patrick J Hanley, Jane Healy, Wen Liu, Brittany A McKelvey, Laura Pearce, Shari Pilon-Thomas, Hillary S Andrews, Monica Veldman, Judy Vong, Susan P Weinbach, Jeff D Allen
BACKGROUND: Significant advancements have been made in the field of cellular therapy as anti-cancer treatments, with the approval of chimeric antigen receptor (CAR)-T cell therapies and the development of other genetically engineered cellular therapies. CAR-T cell therapies have demonstrated remarkable clinical outcomes in various hematological malignancies, establishing their potential to change the current cancer treatment paradigm. Due to the increasing importance of genetically engineered cellular therapies in the oncology treatment landscape, implementing strategies to expedite development and evidence generation for the next generation of cellular therapy products can have a positive impact on patients...
March 16, 2024: Cytotherapy
https://read.qxmd.com/read/38647505/development-of-a-robotic-cluster-for-automated-and-scalable-cell-therapy-manufacturing
#16
JOURNAL ARTICLE
Alice Melocchi, Brigitte Schmittlein, Alexis L Jones, Yasmine Ainane, Ali Rizvi, Darius Chan, Elaine Dickey, Kelsey Pool, Kenny Harsono, Dorothy Szymkiewicz, Umberto Scarfogliero, Varun Bhatia, Amlesh Sivanantham, Nadia Kreciglowa, Allison Hunter, Miguel Gomez, Adrian Tanner, Marco Uboldi, Arpit Batish, Joanna Balcerek, Mariella Kutova-Stoilova, Sreenivasan Paruthiyil, Luis A Acevedo, Rachel Stadnitskiy, Sabrina Carmichael, Holger Aulbach, Matthew Hewitt, Xavier De Mollerat Du Jeu, Benedetta di Robilant, Federico Parietti, Jonathan H Esensten
BACKGROUND AIMS: The production of commercial autologous cell therapies such as chimeric antigen receptor T cells requires complex manual manufacturing processes. Skilled labor costs and challenges in manufacturing scale-out have contributed to high prices for these products. METHODS: We present a robotic system that uses industry-standard cell therapy manufacturing equipment to automate the steps involved in cell therapy manufacturing. The robotic cluster consists of a robotic arm and customized modules, allowing the robot to manipulate a variety of standard cell therapy instruments and materials such as incubators, bioreactors, and reagent bags...
March 15, 2024: Cytotherapy
https://read.qxmd.com/read/38520411/human-embryonic-stem-cell-derived-mesenchymal-stromal-cells-suppress-inflammation-in-mouse-models-of-rheumatoid-arthritis-and-lung-fibrosis-by-regulating-t-cell-function
#17
JOURNAL ARTICLE
Yan Zhong, Yisheng Zhu, Xiaohao Hu, Lin Zhang, Jiahuan Xu, Qingwen Wang, Jingfeng Liu
BACKGROUND AIMS: Rheumatoid arthritis (RA) is characterized by an overactive immune system, with limited treatment options beyond immunosuppressive drugs or biological response modifiers. Human embryonic stem cell-derived mesenchymal stromal cells (hESC-MSCs) represent a novel alternative, possessing diverse immunomodulatory effects. In this study, we aimed to elucidate the therapeutic effects and underlying mechanisms of hESC-MSCs in treating RA. METHODS: MSC-like cells were differentiated from hESC (hESC-MSCs) and cultured in vitro...
March 15, 2024: Cytotherapy
https://read.qxmd.com/read/38556961/protocol-improvement-and-multisite-validation-of-a-digital-soft-agar-colony-formation-assay-for-tumorigenic-transformed-cells-intermingled-in-cell-therapy-products
#18
JOURNAL ARTICLE
Kiyoko Bando, Shinji Kusakawa, Hideki Adachi, Mika Yamamoto, Miki Iwata, Atsushi Kitanaka, Eiichiro Ogimura, Tomoharu Osada, Maya Tamura, Orie Terai, Takeshi Watanabe, Tomomi Yoda, Takafumi Yotsumoto, Kinuko Zaizen, Yoji Sato
BACKGROUND AIMS: The administration of human cell-processed therapeutic products (hCTPs) is associated with a risk of tumorigenesis due to the transformed cellular contaminants. To mitigate this risk, these impurities should be detected using sensitive and validated assays. The digital soft agar colony formation (D-SAC) assay is an ultrasensitive in vitro test for detecting tumorigenic transformed cells in hCTPs. METHODS: In this study, we first evaluated the colony formation efficiency (CFE) precision of tumorigenic reference cells in positive control samples according to a previously reported D-SAC assay protocol (Protocol I) from multiple laboratories...
March 13, 2024: Cytotherapy
https://read.qxmd.com/read/38625071/car-t-cell-expansion-platforms-yield-distinct-t-cell-differentiation-states
#19
JOURNAL ARTICLE
Hannah W Song, Michaela Prochazkova, Lipei Shao, Roshini Traynor, Sarah Underwood, Mary Black, Vicki Fellowes, Rongye Shi, Marie Pouzolles, Hsien-Chao Chou, Adam T Cheuk, Naomi Taylor, Ping Jin, Robert P Somerville, David F Stroncek, Javed Khan, Steven L Highfill
With investigators looking to expand engineered T cell therapies such as CAR-T to new tumor targets and patient populations, a variety of cell manufacturing platforms have been developed to scale manufacturing capacity using closed and/or automated systems. Such platforms are particularly useful for solid tumor targets, which typically require higher CAR-T cell doses. Although T cell phenotype and function are key attributes that often correlate with therapeutic efficacy, how manufacturing platforms influence the final CAR-T cell product is currently unknown...
March 12, 2024: Cytotherapy
https://read.qxmd.com/read/38573277/filling-the-gap-the-workforce-of-tomorrow-for-cgt-manufacturing-as-the-sector-advances
#20
JOURNAL ARTICLE
Emily Hopewell, Nirupama Rupa Pike, Josephine Lembong, Matthew Hewitt, Natalie Fekete
Workforce education and development are key cornerstones in advancing and maturing the Cell & Gene Therapy sector. A skilled worker shortage can significantly impact and delay progress as well as the quality of output for any developer, thereby negatively impacting a patient's access to life-saving treatments. Several roundtable discussions were held at the International Society for Cell & Gene Therapy (ISCT) 2023 Annual Meeting to dive deeper into the current state of workforce development and solutions to address this bottleneck...
March 12, 2024: Cytotherapy
journal
journal
34796
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.